Novo Nordisk and GE HealthCare collaborate on ultrasound technology for weight loss and diabetes
From Investing.com: 2025-01-23 11:56:00
The GLP-1 market is revolutionizing weight loss and obesity treatment, with Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide leading the charge. Despite high costs, supply shortages persist, and insurers are becoming more hesitant to cover treatments. Meanwhile, Novo Nordisk and GE HealthCare are developing a novel ultrasound technology for weight loss and diabetes management.
Novo Nordisk’s collaboration with GE HealthCare on peripheral-focused ultrasound (PFUS) shows promising results in regulating metabolic functions. The technology uses ultrasound to stimulate nerve pathways and improve glucose metabolism in patients with type 2 diabetes, offering a potential non-invasive treatment option.
Novo Nordisk’s latest innovation, CagriSema, combines an amylin analog with semaglutide for significant weight loss results in obese individuals with type 2 diabetes. Phase 3 trials demonstrated superior weight loss compared to individual components, but the market reacted with a sell-off after the announcement. Capacity constraints continue to challenge Novo Nordisk’s ability to compete effectively against Eli Lilly.
Despite Novo Nordisk’s struggles, the company remains a key player in the GLP-1 market. Supply shortages for popular treatments like Ozempic and Wegovy have driven up demand, leading to soaring sales for providers like Hims Hers Health Inc. Investors may see opportunity in Novo Nordisk’s declining stock price and potential for future growth in the weight loss and obesity treatment sector.
Read more at Investing.com: Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play